Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression.
In conclusion, germacrone reversed adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-gp expression. The results indicated that germacrone might be a new MDR reversal agent for CML chemotherapy.
PMID: 29655913 [PubMed - as supplied by publisher]
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Pan J, Miao D, Chen L Tags: Chem Biol Interact Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemistry | Chemotherapy | Chronic Leukemia | Chronic Myeloid Leukaemia | Genetics | Leukemia | Molecular Biology | Multidrug Resistance | Study